Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Non-Small Cell Lung Cancer Metastatic × tepotinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 4 Neoplasms 2 Non-Small Cell Lung Cancer Metastatic 1 Lung Neoplasms 1 Hematologic Neoplasms 1 Gastrointestinal Neoplasms 1 Deafness, Autosomal Recessive 39 1 Colorectal Neoplasms 1 Breast Neoplasms 1 Adenocarcinoma 1

Interventions

tepotinib 1 patritumab deruxtecan 1 lazertinib 1 durvalumab 1 Pemetrexed 1 Cisplatin 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06106802 2026-02-23

Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment

Samsung Medical Center

Phase 2 Recruiting

Non-Small Cell Lung Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡